305 related articles for article (PubMed ID: 36639296)
21. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
22. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia.
Goebell PJ; Raina R; Chen S; Rege S; Shah R; Grossman JP; Waldeck AR
Future Oncol; 2024 May; 20(14):903-918. PubMed ID: 38353055
[TBL] [Abstract][Full Text] [Related]
23. A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2).
Crabb S; Morgan A; Hunter MS; Stefanopoulou E; Griffiths G; Richardson A; Fenlon D; Fleure L; Raftery J; Boxall C; Wilding S; Nuttall J; Eminton Z; Tilt E; O'Neill A; Bacon R; Martin J
Trials; 2023 Jul; 24(1):450. PubMed ID: 37430353
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.
Alwhaibi A; Alsanea S; Almadi B; Al-Sabhan J; Alosaimi FD
Aging Male; 2022 Dec; 25(1):101-124. PubMed ID: 35343371
[No Abstract] [Full Text] [Related]
25. The evolving role of androgen deprivation therapy in the management of prostate cancer.
Cooperberg MR; Small EJ; D'Amico A; Carroll PR
Minerva Urol Nefrol; 2003 Dec; 55(4):219-38. PubMed ID: 14765015
[TBL] [Abstract][Full Text] [Related]
26. Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.
Fizazi K; Abrahamsson PA; Ahlgren G; Bellmunt J; Castellano D; Culine S; de Wit R; Gillessen S; Gschwend JE; Hamdy F; James N; McDermott R; Miller K; Wiegel T; Wirth M; Tombal B
Eur Urol; 2015 May; 67(5):904-12. PubMed ID: 25218582
[TBL] [Abstract][Full Text] [Related]
27. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.
Tully KH; Nguyen DD; Herzog P; Jin G; Noldus J; Nguyen PL; Kibel AS; Sun M; McGregor B; Basaria S; Trinh QD
Eur Urol Oncol; 2021 Feb; 4(1):66-72. PubMed ID: 31624049
[TBL] [Abstract][Full Text] [Related]
28. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
[TBL] [Abstract][Full Text] [Related]
29. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
[TBL] [Abstract][Full Text] [Related]
30. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
31. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
32. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
Schulman C; Irani J; Aapro M
BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
[TBL] [Abstract][Full Text] [Related]
33. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
35. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
[TBL] [Abstract][Full Text] [Related]
36. Post-prostatectomy adjuvant androgen deprivation therapy- Current opinions and practices of Canadian urologists.
Levitt M; Nayak AL; Fergusson DA; Lavallee LT; Morash C; Cagiannos I; Flaman AS; Breau RH
Urol Oncol; 2022 Feb; 40(2):57.e9-57.e14. PubMed ID: 34303596
[TBL] [Abstract][Full Text] [Related]
37. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
[TBL] [Abstract][Full Text] [Related]
38. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
39. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
[TBL] [Abstract][Full Text] [Related]
40. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
